TY - JOUR
T1 - Optimal Management of Dysphagia in Patients with Inoperable Esophageal Cancer
T2 - Current Perspectives
AU - Mohapatra, Sonmoon
AU - Santharaman, Aadhithyaraman
AU - Gomez, Krista
AU - Pannala, Rahul
AU - Kachaamy, Toufic
N1 - Funding Information:
Toufic Kachaamy: Consultant for Medtronic, Steris, Pentax, Microtech. Receives educational support from Boston Scientific and Cook. Rahul Pannala: Research funding from ERBE, USA, consulting fees from HCL technologies, personal fees from Bluestar Genomics and Nestle Health Sciences, and grants from Fractyl Labs. All other authors have no financial disclosures.
Publisher Copyright:
© 2022 Mohapatra et al.
PY - 2022
Y1 - 2022
N2 - The majority of patients with esophageal cancer are diagnosed at an advanced, incurable stage. Palliation of symptoms, specifically dysphagia, is a crucial component to improve quality of life and optimize nutritional status. Despite multiple available treatment modalities, there is not one accepted or recommended to be the preferred treatment option. Palliative management is often decided by a multidisciplinary team considering factors including local availability, preference, patient life expectancy, and symptom severity. Systemic therapies such as chemotherapy are the most commonly used palliative modalities. Oncologists are most familiar with radiation for dysphagia palliation, especially for advanced metastatic cancer patients with good performance status. One common approach used by endoscopist is self-expandable metal stents. This is preferred for patients with short-term survival and poor functional status as it provides rapid relief of dysphagia. Cryotherapy is a relatively new endoscopic ablative modality and appears to be a promising option for dysphagia palliation, but more data is needed for wider adoption. This review summarizes the current literature on endoscopic and non-endoscopic treatment options for malignant dysphagia.
AB - The majority of patients with esophageal cancer are diagnosed at an advanced, incurable stage. Palliation of symptoms, specifically dysphagia, is a crucial component to improve quality of life and optimize nutritional status. Despite multiple available treatment modalities, there is not one accepted or recommended to be the preferred treatment option. Palliative management is often decided by a multidisciplinary team considering factors including local availability, preference, patient life expectancy, and symptom severity. Systemic therapies such as chemotherapy are the most commonly used palliative modalities. Oncologists are most familiar with radiation for dysphagia palliation, especially for advanced metastatic cancer patients with good performance status. One common approach used by endoscopist is self-expandable metal stents. This is preferred for patients with short-term survival and poor functional status as it provides rapid relief of dysphagia. Cryotherapy is a relatively new endoscopic ablative modality and appears to be a promising option for dysphagia palliation, but more data is needed for wider adoption. This review summarizes the current literature on endoscopic and non-endoscopic treatment options for malignant dysphagia.
KW - cryotherapy
KW - esophageal cancer
KW - external beam radiation therapy
KW - self-expandable metal stent
UR - http://www.scopus.com/inward/record.url?scp=85146987005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146987005&partnerID=8YFLogxK
U2 - 10.2147/CMAR.S362666
DO - 10.2147/CMAR.S362666
M3 - Review article
AN - SCOPUS:85146987005
SN - 1179-1322
VL - 14
SP - 3281
EP - 3291
JO - Cancer Management and Research
JF - Cancer Management and Research
ER -